Survodutide is a cutting-edge, long-acting synthetic peptide that functions as a dual Glucagon/GLP-1 receptor agonist, representing a major advancement in the treatment of obesity, metabolic disorders, and MASH (metabolic dysfunction-associated steatohepatitis). By activating the GLP-1 receptor, it effectively suppresses appetite and delays gastric emptying, while its unique simultaneous activation of the glucagon receptor directly boosts energy expenditure, calorie burning, and liver fat clearance; this dual-action mechanism delivers exceptional, high-magnitude weight loss and profound metabolic improvements, positioning it as a powerful contender in the next generation of metabolic therapies.
Reviews
There are no reviews yet.